Aurelius Omlin

Aurelius Omlin is a Swiss genitourinary oncologist who has been active in the ARASENS trial and other mHSPC investigations examining darolutamide plus docetaxel plus ADT triplet therapy. He participates in the Advanced Prostate Cancer Consensus Conference and contributes to European treatment guidelines for hormone-sensitive prostate cancer. His clinical research focuses on treatment intensification strategies and patient selection for triplet versus doublet approaches in mHSPC. Omlin has presented at major oncology meetings and contributes to international mHSPC treatment debates.